Global Active Implantable Medical Devices Market -2023-2030

Global Active Implantable Medical Devices Market -2023-2030

Global Active Implantable Medical Devices Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.

An active implantable medical device is an active medical device intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes. An active implantable medical device includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

Active implantable medical devices are designed to remain in direct contact with the body for extended periods and they are subject to rigorous standards and requirements to protect the health and safety of patients. Active implantable medical devices are also widely used in various applications such as in the cardiovascular, neurology, and orthopedic.

Market Dynamics

Increasing device launches

The increasing number of product launches for active implantable medical devices acts as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new treatment devices.

For instance, in May 2023, MicroPort CRM received U.S. FDA approval for its latest range of implantable pacemakers, AlizeaTM and CeleaTM. These are modern pacemaker technology that is small and discrete under the skin, making it easier to implant.

Also, in December 2022, Medtronic launched a deep brain implantable stimulator called Percept PC which is equipped with technology called BrainSense to provide electrical deep brain stimulation (DBS) treatment to patients with neurological diseases such as Parkinson's disease.

Additionally, in August 2022, Medtronic plc. launched an extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with a lead put under the breastbone.

Furthermore, significant growth drivers such as the rising prevalence and incidence of chronic diseases, and the growing adoption of minimally invasive surgeries by using active implantable medical devices are expected to drive the market in the forecast period.

Complications related to implantable pacemakers

The complications related to implanted pacemakers will hamper the market growth in the forecast period. As per the Mayo Clinic, swelling, bleeding, or bruising can occur at the pacemaker site, particularly if the patient is taking blood thinners. It can also cause thromboembolism (blood clots) near the pacemaker site or the blood vessel or nerve damage near the pacemaker.

Segment Analysis

The global active implantable medical devices market is segmented based on device type, application, end users, and region.

Neurostimulators accounted for approximately 47.3% of the market share

An implantable neurostimulator delivers mild electrical signals to the epidural space near the spine through thin wires called leads. Neurostimulators are expected to hold the largest market share over the period forecast owing to increasing new neurostimulator launches and technical advancements.

For instance, in April 2023, Synapse Biomedical, Inc. launched the NeuRx Diaphragm Pacing System which is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy.

Additionally, in December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system which is the smallest implantable, rechargeable spinal cord stimulator for the treatment of chronic pain.

Geographical Analysis

North America is expected to hold a significant position in the global active implantable medical devices market share

The global active implantable medical devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of atrial fibrillation, and increasing adoption of cardiac pacemaker implantation, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health 2022, it is estimated that in the United States, the number of people with an implantable pacemaker is between 500,000 and 3 million. The chance of pacemaker implantation increases with age for over 70% of all pacemakers that are implanted in patients over the age of 65.

Additionally, according to Healthline Media, it is estimated that the prevalence of atrial fibrillation in the United States ranges from about 2.7 million to 6.1 million. It is estimated to rise to 12.1 million in 2030. Hence, due to the increasing number of people with atrial fibrillation, the rate of pacemaker implantation is expected to increase to treat heart diseases.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global active implantable medical devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the active implantable medical devices market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include Boston Scientific Corporation, Medtronic Plc, MED-EL, Nurotron Biotechnology Co. Ltd., Abbott Laboratories, Cochlear Ltd, Sanova Holding AG, LivaNova Plc, Biotronik Inc., Osypka Medical among others.

Key Developments
• In June 2023, Medics invested £1.8 million for clinical trials with the aim of precisely targeting heart patients who need tiny defibrillators to be fitted under their skin with the aim of reducing deaths from sudden cardiac arrests.
• In June 2021, India Medtronic Private Limited launched Micra AV, a little, a fully self-contained pacemaker that uses a minimally invasive method to provide sophisticated pacing technology to those with atrioventricular (AV) block.

Why Purchase the Report?
• To visualize the global active implantable medical devices market segmentation based on device type, application, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of active implantable medical devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global active implantable medical devices market report would provide approximately 61 tables, 62 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies